Journal
CELL DEATH DISCOVERY
Volume 7, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41420-021-00744-1
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81573658]
- Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030, 2020B1212060034]
Ask authors/readers for more resources
The study shows that gefitinib downregulates Sterol Regulator Element Binding (SREBP1) in therapy-sensitive cells but not in cells with acquired resistance. Lipidomics analysis reveals different changes in lipid composition in gefitinib-sensitive and acquired-resistant cells. Inhibition of SREBP1 sensitizes EGFR-mutant therapy-resistant NSCLC to gefitinib.
Patients with EGFR mutations in non-small cell lung cancer (NSCLC) have been greatly benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired resistance. In this study, we show that gefitinib significantly induces downregulation of Sterol Regulator Element Binding (SREBP1) in therapy-sensitive cells. However, this was not observed in EGFR mutant NSCLC cells with acquired resistance. Lipidomics analysis showed that gefitinib could differently change the proportion of saturated phospholipids and unsaturated phospholipids in gefitinib-sensitive and acquired-resistant cells. Besides, levels of ROS and MDA were increased upon SREBP1 inhibition and even more upon gefitinib treatment. Importantly, inhibition of SREBP1 sensitizes EGFR-mutant therapy-resistant NSCLC to gefitinib both in vitro and in vivo models. These data suggest that sustained de novo lipogenesis through the maintenance of active SRBEP-1 is a key feature of acquired resistance to gefitinib in EGFR mutant lung cancer. Taken together, targeting SREBP1-induced lipogenesis is a promising approach to overcome acquired resistance to gefitinib in EGFR-mutant lung cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available